Bone Biologics Corp. (NASDAQ:BBLG) Short Interest Update

Bone Biologics Corp. (NASDAQ:BBLG) was the recipient of a significant decline in short interest in March. As of March 13th, there was short interest totaling 26,183 shares, a decline of 13.8% from the February 26th total of 30,363 shares. Based on an average trading volume of 30,831 shares, the short-interest ratio is currently 0.8 days. Currently, 1.6% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Bone Biologics in a report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Institutional Trading of Bone Biologics

An institutional investor recently raised its position in Bone Biologics stock. DRW Securities LLC grew its stake in Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 23,576 shares of the company’s stock after buying an additional 12,549 shares during the quarter. DRW Securities LLC owned 1.31% of Bone Biologics worth $34,000 as of its most recent SEC filing. Institutional investors own 34.30% of the company’s stock.

Bone Biologics Trading Up 5.5%

Shares of BBLG opened at $1.16 on Thursday. The stock has a fifty day moving average price of $1.30 and a 200-day moving average price of $1.73. Bone Biologics has a 12 month low of $1.05 and a 12 month high of $6.75. The firm has a market cap of $2.08 million, a PE ratio of -0.31 and a beta of 0.78.

Bone Biologics (NASDAQ:BBLG) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($0.34) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.34). As a group, research analysts forecast that Bone Biologics will post -5 EPS for the current year.

About Bone Biologics

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.